Literature DB >> 27859493

Connexin32 deficiency is associated with liver injury, inflammation and oxidative stress in experimental non-alcoholic steatohepatitis.

Taynã Cristina Tiburcio1, Joost Willebrords2, Tereza Cristina da Silva1, Isabel Veloso Alves Pereira1, Marina Sayuri Nogueira3, Sara Crespo Yanguas2, Michaël Maes2, Elisangela Dos Anjos Silva1, Maria Lucia Zaidan Dagli1, Inar Alves de Castro3, Cláudia Pinto Oliveira4, Mathieu Vinken2, Bruno Cogliati1.   

Abstract

Non-alcoholic steatohepatitis is a highly prevalent liver pathology featured by hepatocellular fat deposition and inflammation. Connexin32, which is the major building block of hepatocellular gap junctions, has a protective role in hepatocarcinogenesis and is downregulated in chronic liver diseases. However, the role of connexin32 in non-alcoholic steatohepatitis remains unclear. Connexin32-/- mice and their wild-type littermates were fed a choline-deficient high-fat diet. The manifestation of non-alcoholic steatohepatitis was evaluated based on a battery of clinically relevant read-outs, including histopathological examination, diverse indicators of inflammation and liver damage, in-depth lipid analysis, assessment of oxidative stress, insulin and glucose tolerance, liver regeneration and lipid-related biomarkers. Overall, more pronounced liver damage, inflammation and oxidative stress were observed in connexin32-/- mice compared to wild-type animals. No differences were found in insulin and glucose tolerance measurements and liver regeneration. However, two lipid-related genes, srebf1 and fabp3, were upregulated in Cx32-/- mice in comparison with wild-type animals. These findings suggest that connexin32-based signalling is not directly involved in steatosis as such, but rather in the sequelae of this process, which underlie progression of non-alcoholic steatohepatitis.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  connexin32; inflammation; liver damage; non-alcoholic steatohepatitis; oxidative stress; steatosis

Mesh:

Substances:

Year:  2017        PMID: 27859493      PMCID: PMC5689377          DOI: 10.1111/1440-1681.12701

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  43 in total

1.  Purification and characterization of the flavoenzyme glutathione reductase from rat liver.

Authors:  I Carlberg; B Mannervik
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

Review 2.  Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease.

Authors:  Vettickattuparambil George Giby; Thekkuttuparambil Ananthanarayanan Ajith
Journal:  World J Hepatol       Date:  2014-08-27

Review 3.  Leptin in nonalcoholic fatty liver disease: a narrative review.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-10-23       Impact factor: 8.694

Review 4.  Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.

Authors:  Detlef Schuppan; Jörn M Schattenberg
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

Review 5.  Connexin modulators and their potential targets under the magnifying glass.

Authors:  S B Bodendiek; G Raman
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 6.  Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.

Authors:  P Pettinelli; A M Obregón; L A Videla
Journal:  Nutr Hosp       Date:  2011 May-Jun       Impact factor: 1.057

7.  Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats.

Authors:  Hiroyuki Sagawa; Aya Naiki-Ito; Hiroyuki Kato; Taku Naiki; Yoriko Yamashita; Shugo Suzuki; Shinya Sato; Kosuke Shiomi; Akihisa Kato; Toshiya Kuno; Yoichi Matsuo; Masahiro Kimura; Hiromitsu Takeyama; Satoru Takahashi
Journal:  Carcinogenesis       Date:  2015-10-22       Impact factor: 4.944

8.  Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis.

Authors:  Sang Dal Rhee; Chi-Hyun Kim; Ji Seon Park; Won Hoon Jung; Sung Bum Park; Hee Youn Kim; Gyu Hwan Bae; Ta Jan Kim; Ki Young Kim
Journal:  Eur J Pharmacol       Date:  2012-06-26       Impact factor: 4.432

9.  Gap junction dysfunction reduces acetaminophen hepatotoxicity with impact on apoptotic signaling and connexin 43 protein induction in rat.

Authors:  Aya Naiki-Ito; Makoto Asamoto; Taku Naiki; Kumiko Ogawa; Satoru Takahashi; Shinya Sato; Tomoyuki Shirai
Journal:  Toxicol Pathol       Date:  2010-01-22       Impact factor: 1.902

10.  Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.

Authors:  Siva Sankara Vara Prasad Sakamuri; Mahesh Sukapaka; Vijay Kumar Prathipati; Harishankar Nemani; Uday Kumar Putcha; Shailaja Pothana; Swarupa Rani Koppala; Lakshmi Raj Kumar Ponday; Vani Acharya; Giridharan Nappan Veetill; Vajreswari Ayyalasomayajula
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more
  7 in total

1.  Connexin32 ameliorates renal fibrosis in diabetic mice by promoting K48-linked NADPH oxidase 4 polyubiquitination and degradation.

Authors:  Zhiquan Chen; Xiaohong Sun; Qiuhong Chen; Tian Lan; Kaipeng Huang; Haiming Xiao; Zeyuan Lin; Yan Yang; Peiqing Liu; Heqing Huang
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

Review 2.  The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone.

Authors:  Nils Haep; Rodrigo M Florentino; James E Squires; Aaron Bell; Alejandro Soto-Gutierrez
Journal:  Semin Liver Dis       Date:  2021-05-15       Impact factor: 6.115

3.  Intercellular Transmission of Hepatic ER Stress in Obesity Disrupts Systemic Metabolism.

Authors:  Amir Tirosh; Gurol Tuncman; Ediz S Calay; Moran Rathaus; Idit Ron; Amit Tirosh; Abdullah Yalcin; Yankun G Lee; Rinat Livne; Sophie Ron; Neri Minsky; Ana Paula Arruda; Gökhan S Hotamisligil
Journal:  Cell Metab       Date:  2020-12-18       Impact factor: 27.287

4.  Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice.

Authors:  Joost Willebrords; Bruno Cogliati; Isabel Veloso Alves Pereira; Tereza Cristina da Silva; Sara Crespo Yanguas; Michaël Maes; Veronica Mollica Govoni; Andressa Lima; Daniele Aparecida Felisbino; Elke Decrock; Marina Sayuri Nogueira; Inar Alves de Castro; Isabelle Leclercq; Luc Leybaert; Robim Marcelino Rodrigues; Mathieu Vinken
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

5.  Cholestasis Differentially Affects Liver Connexins.

Authors:  Axelle Cooreman; Raf Van Campenhout; Sara Crespo Yanguas; Eva Gijbels; Kaat Leroy; Alanah Pieters; Andrés Tabernilla; Pieter Van Brantegem; Pieter Annaert; Bruno Cogliati; Mathieu Vinken
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

6.  Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity.

Authors:  Jay Luther; Manish K Gala; Nynke Borren; Ricard Masia; Russell P Goodman; Ida Hatoum Moeller; Erik DiGiacomo; Alyssa Ehrlich; Andrew Warren; Martin L Yarmush; Ashwin Ananthakrishnan; Kathleen Corey; Lee M Kaplan; Sangeeta Bhatia; Raymond T Chung; Suraj J Patel
Journal:  Hepatol Commun       Date:  2018-07-16

7.  Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.

Authors:  Joost Willebrords; Michaël Maes; Isabel Veloso Alves Pereira; Tereza Cristina da Silva; Veronica Mollica Govoni; Valéria Veras Lopes; Sara Crespo Yanguas; Valery I Shestopalov; Marina Sayuri Nogueira; Inar Alves de Castro; Anwar Farhood; Inge Mannaerts; Leo van Grunsven; Jephte Akakpo; Margitta Lebofsky; Hartmut Jaeschke; Bruno Cogliati; Mathieu Vinken
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-12       Impact factor: 5.187

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.